Consequences of long-term proton pump blockade: Insights from studies of patients with gastrinomas

Basic and Clinical Pharmacology and Toxicology

Volumn 98, Issue 1, 2006, Pages 4-19

  Jensen, Robert T ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; FERRITIN; GASTRIN; HISTAMINE; HISTAMINE H2 RECEPTOR ANTAGONIST; IRON; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE; STOMACH SECRETION INHIBITOR;

ACHLORHYDRIA; ATROPHIC GASTRITIS; CYANOCOBALAMIN DEFICIENCY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERANCE; DYSPEPSIA; DYSPLASIA; EPIDEMIOLOGICAL DATA; ERADICATION THERAPY; EXPERIMENTAL ANIMAL; EXPERIMENTAL MOUSE; FERRITIN BLOOD LEVEL; GASTRINOMA; GASTRITIS; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTAMINE RELEASE; HUMAN; HYPERCHLORHYDRIA; HYPERGASTRINEMIA; HYPERPLASIA; IDIOPATHIC DISEASE; INCIDENCE; INFECTION RISK; IRON DEFICIENCY; LIVER METASTASIS; LONG TERM CARE; MALABSORPTION; NODULAR HYPERPLASIA; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SEX DIFFERENCE; SHORT SURVEY; STOMACH CANCER; STOMACH CARCINOID; STOMACH EMPTYING; STOMACH PARESIS; TREATMENT DURATION; VAGUS NERVE; ZOLLINGER ELLISON SYNDROME;

ANIMALS; CARCINOID TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DRUG TOLERANCE; ENTEROCHROMAFFIN-LIKE CELLS; GASTRIC ACID; GASTRIC MUCOSA; GASTRINOMA; GASTRINS; GASTRITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL AGENTS; HELICOBACTER PYLORI; HUMANS; MALABSORPTION SYNDROMES; PEPTIC ULCER; PROTON PUMPS; STOMACH NEOPLASMS; TIME FACTORS; ZOLLINGER-ELLISON SYNDROME;

ANIMALIA; HELICOBACTER; HELICOBACTER PYLORI;

EID: 33645107796     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2006.pto_378.x     Document Type: Short Survey

References (222)

1. Anonymous Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group Gut 1997 41 8 13
2. Abdalla S. I. P. Lao-Sirieix M. R. Novelli L. B. Lovat I. R. Sanderson R. C. Fitzgerald Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis Clin. Cancer Res. 2004 10 4784 4792
3. Aly A. A. Shulkes G. S. Baldwin Gastrins, cholecystokinins and gastrointestinal cancer Biochim. Biophys. Acta 2004 1704 1 10
4. Armstrong D. Long-term safety and efficacy of omeprazole in gastro-oesophageal reflux disease Lancet 2000 356 610 612
5. Baba M. K. Itoh M. Tatsuta Glycine-extended gastrin induces matrix metalloproteinase-1- and -3 mediated invasion of human colon cancer cells through type I collagen gel and Matrigel Int. J. Cancer 2005 111 23 31
6. Baldwin G. S. The role of gastrin and cholecystokinin in normal and neoplastic gastrointestinal growth J. Gastroenterol. Hepatol. 1995 10 215 232
7. Baldwin G. S. A. Shulkes Gastrin as an autocrine growth factor in colorectal carcinoma: implications for therapy World J. Gastroenterol. 1998a 4 461 463
8. Baldwin G. S. A. Shulkes Gastrin, gastrin receptors and colorectoral carcinoma Gut 1998b 42 581 584
9. Bellou A. I. Aimone-Gastrin J. D. De Korwin J. P. Bronowicki A. Moneret-Vautrin J. P. Nicolas M. A. Bigard J. L. Gueant Cobalamin deficiency with megaloblastic anaemia in one patient under longterm omeprazole therapy J. Intern. Med. 1996 240 161 164
10. Berstad A. E. J. G. Hatlebakk H. Maartmann-Moe A. Berstad P. Brandtzaeg Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole Gut 1997 41 740 747
11. Bezwoda W. R. Charlton T. Bothwell J. Torrance F. Mayet The importance of gastric hydrochloric acid in the absorption of nonheme food iron J. Lab. Clin. Med. 1978 92 108 116
12. Borch K. E. Kullman S. Hallhagen T. Ledin I. Ihse Increased incidence of pancreatic neoplasia in pernicious anemia World J. Surg. 1988 12 866 870
13. Borch K. H. Renvall G. Liedberg Gastric endocrine cell hyperplasia and carcinoid tumors in pernicious anemia Gastroenterology 1985 88 638 648
14. Borch K. H. Renvall G. Liedberg B. N. Andersen Relations between circulating gastrin and endocrine cell proliferation in the atrophic gastric fundic mucosa Scand. J. Gastroenterol. 1986 21 357 363
15. Bordi C. C. Azzoni G. Ferraro V. D. Corleto F. Gibril G. Delle Fave I. A. Lubensky D. J. Venzon R. T. Jensen Sampling strategies for analysis of enterochromaffin-like cell changes in Zollinger-Ellison syndrome Amer. J. Clin. Pathol. 2000 114 419 425
16. Bordi C. T. D'Adda C. Azzoni F. P. Pilato P. Caruana Hypergastrinemia and gastric enterochromaffinlike cells Amer. J. Surg. Pathol. 1995 19 S8 S19
17. Bordi C. T. D'Adda F. P. Pilato C. Ferrari Carcinoid (ECL cell) tumor of the oxyntic mucosa of the stomach: a hormone-dependent neoplasm? In Progress in surgical pathology vol. 8 Eds. Fenoglio-Preiser C. Wolff M. Rilke F. Field & Wood Philadelphia 1988 pp. 177 195
18. Brinton L. A. G. Gridley Z. Hrubeck R. Hoover J. F. Fraumeni Jr.. Cancer risk following pernicious anaemia Brit. J. Cancer 1989 89 810 813
19. Buchan A. M. J. S. Grant H. J. Freeman Regulatory peptides in Barrett's oesophagus J. Pathol. 1985 146 227 234
20. Cadiot G. T. Lehy P. Ruszniewski S. Bonfils M. Mignon Gastric endocrine cell evolution in patients with Zollinger-Ellison syndrome. Influence of gastrinoma growth and long-term omeprazole treatment Dig. Dis. Sci. 1993 38 1307 1317
21. Cadiot G. C. Vissuzaine F. Potet M. Mignon Fundic argyrophil carcinoid tumor in a patient with sporadic-type Zollinger-Ellison syndrome Dig. Dis. Sci. 1995 40 1275 1278
22. Caplin M. K. Khan S. Grimes D. Michaeli K. Savage R. Pounder A. Dhillon Effect of gastrin and anti-gastrin antibodies on proliferation of hepatocyte cell lines Dig. Dis. Sci. 2001 46 1356 1366
23. Carney J. A. V. L. W. Go J. F. Fairbanks S. B. Moore E. C. Alport E. E. Nora The syndrome of gastric argytrophil carcinoid tumors and nonantral gastric atropy Ann. Intern. Med. 1983 99 761 766
24. Chu M. F. C. Nielsen L. Franzen J. F. Rehfeld J. J. Holst K. Borch Effect of endogenous hypergastrinemia on gastrin receptor expressing human colon carcinoma transplanted to athymic rats Gastroenterology 1995 109 1415 1420
25. Clere P. M. Dufresne C. Saillan E. Chastre T. Andre C. Escrieut K. Kennedy N. Vaysse C. Gespach D. Fourmy Differential expression of the CCK-A and CCK-B/gastrin receptor genes in human cancers of the esophagus, stomach and colon Int. J. Cancer 1997 72 931 936
26. Collen M. J. J. M. Howard K. E. McArthur J. P. Raufman M. J. Cornelius C. A. Ciarleglio J. D. Gardner R. T. Jensen Comparison of ranitidine and cimetidine in the treatment of gastric hypersecretion Ann. Intern. Med. 1984 100 52 58
27. Conrad M. E. Iron absorption In Physiology of the gastrointestinal tract 2nd ed. Ed. Johnson L. R. Raven Press New York 1987 pp. 1437 1453
28. Coupe M. H. Rees C. J. Springer A. E. Bishop J. A. Morris J. M. Polak J. Calam Gastric enterochromaffin-like (ECL) cells in hypergastrinaemic duodenal ulcer disease Gut 1990 31 144 147
29. Creutzfeldt R. R. Lamberts F. Stockmann G. Brunner Quantitative studies of gastric endocrine cells in patients receiving long-term treatment with omeprazole Scand. J. Gastroenterol. 1989 24 122 128
30. Creutzfeldt W. Consequences of gastric acid inhibition in man In Proton pump inhibitors Ed. Olbe L. Birkhauser Verlag Basel, Switzerland 1999 pp. 91 115
31. Creutzfeldt W. The achlorhydria-carcinoid sequence: role of gastrin Digestion 1988 39 61 79
32. Creutzfeldt W. R. Lamberts Is hypergastrinemia dangerous to man? Scand. J. Gastroenterol. 1991 180 Suppl. 179 191
33. D'Adda T. V. Corleto F. P. Pilato M. T. Baggi F. Robutti G. Delle Fave C. Bordi Quantitative ultrastructure of endocrine cells of oxyntic mucosa in Zollinger-Ellison syndrome. Correspondence with light microscopic findings Gastroenterology 1990 99 17 26
34. de Leval L. N. Hardy M. Deprez J. Delwaide J. Belaiche J. Boniver Gastric collision between a papillotubular adenocarcinoma and a gastrinoma in a patient with Zollinger-Ellison syndrome Virchows Arch. 2002 441 462 465
35. Delle Fave G. M. Marignani A. Moretti G. D'Ambra G. Martino B. Annibale Hypergastrinemia and enterochromaffin-like cell hyperplasia Yale J. Biol. Med. 1998 71 291 301
36. Dickinson C. J. Relationship of gastrin processing to colon cancer (Editorial) Gastroenterology 1995 109 1384 1388
37. Diebold M. D. S. Richardson A. Duchteau M. A. Bigard R. Colin A. Cortot J. L. Fauchere P. Zeitoun Factors influencing corpus argyrophil cell density and hyperplasia in reflux esophagitis patients treated with antisecretory drugs and controls Dig. Dis. Sci. 1998 43 1629 1635
38. Dutta S. K. Editorial: vitamin B12 malabsorption and omeprazole therapy J. Am. Coll. Nutr. 1994 13 544 545
39. Eason C. T. A. J. Spencer A. Pattison D. D. Howells D. C. Henry F. W. Bonner Species variation in gastric toxicity following chronic administration of ciprofibrate to rat, mouse, and marmoset Toxicol. Appl. Pharmacol. 1988 95 328 338
40. Eissele R. G. Brunner B. Simon E. Solcia R. Arnold Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia Gastroenterology 1997 112 707 717
41. El-Omar E. S. Banerjee A. Wirz I. Penman J. E. Ardill K. E. McColl Marked rebound acid hypersecretion after treatment with ranitidine Amer. J. Gastroenterol. 1996 91 355 359
42. El-Serag H. B. T. V. Aguirre S. Davis M. Kuebeler A. Bhattacharyya R. E. Sampliner Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus Amer. J. Gastroenterol. 2005 99 1877 1883
43. Elsborg L. J. Mosbech Pernicious anaemia as a risk factor in gastric cancer Acta med. scand. 1979 206 315 318
44. Eriksson S. L. Clase I. Moquist-Olsson Pernicious anemia as a risk factor in gastric cancer. The extent of the problem Acta med. scand. 1981 210 481 484
45. Festen H. J. Tertoolen Malabsorption of protein-bound but not unbound cobalamin during treatment with omeprazole Gastroenterology 1988 94 A125
46. Festen H. P. Intrinsic factor secretion and cobalamin absorption. Physiology and pathophysiology in the gastrointestinal tract Scand. J. Gastroenterol. 1991 26 1 7
47. Feurle G. E. Argyrophil cell hyperplasia and a carcinoid tumour in the stomach of a patient with sporadic Zollinger-Ellison syndrome Gut 1994 35 275 277
48. Fich A. N. J. Talley R. G. Shorter S. F. Philips Zollinger-Ellison syndrome. Relation to Helicobacter pylori-associated chronic gastritis and gastric acid secretion Dig. Dis. Sci. 1991 36 10 14
49. Flejou J. F. Barrett's oesophagus: from metaplasia to dysplasia and cancer Gut 2005 54 i6 i12
50. Fossmark R. G. Johnsen E. Johanessen H. L. Waldum Rebound acid hypersecretion after long-term inhibition of gastric acid secretion Aliment. Pharmacol. Ther. 2005a 21 149 154
51. Fossmark R. C. M. Zhao T. C. Martinsen S. Kawase D. Chen H. L. Waldum Dedifferentiation of enterochromaffin-like cells in gastric cancer of hypergastrinemic cotton rats APMIS 2005b 113 436 449
52. Freston J. W. Omeprazole, hypergastrinemia, and gastric carcinoid tumors Ann. Intern. Med. 1994 121 232 233
53. Frucht H. P. N. Maton R. T. Jensen Use of omeprazole in patients with the Zollinger-Ellison syndrome Dig. Dis. Sci. 1991 36 394 404
54. Geboes K. W. Dekker C. J. Mulder K. Nusteling Dutch Study Group Long-term lansoprazole treatment for gastro-oesophageal reflux disease: clinical efficacy and influence on gastric mucosa Aliment. Pharmacol. Ther. 2001 15 1819 1826
55. Gillen D. K. E. McColl Problems associated with the clinical use of proton pump inhibitors Pharmacology & Toxicology 2001a 89 281 286
56. Gillen D. K. E. McColl Problems related to acid rebound and tachyphylaxis Best Pract. Res. Clin. Gastroenterol. 2001b 15 487 495
57. Gillen D. A. A. Wirz J. E. Ardill K. E. McColl Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status Gastroenterology 1999a 116 239 247
58. Gillen D. A. A. Wirz K. E. L. McColl Rebound acid hypersecretion after omeprazole is a prolonged phenomenon Gut 2000 46 W75
59. Gillen D. A. A. Wirz K. E. L. McColl Rebound maximal acid hypersecretion after omeprazole persists to at least 11 months after treatment Gastroenterology 2001 120 A158
60. Gillen D. A. A. Wirz W. D. Neithercut J. E. Ardill K. E. McColl Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole Gut 1999b 44 468 475
61. Golubov J. P. Flanagan P. Adams Inhibition of iron absorption by omeprazole in rat model Dig. Dis. Sci. 1991 36 405 408
62. Gough D. B. G. B. Thompson T. B. Crotty J. H. Donohue L. K. Kvols J. A. Carney C. S. Grant D. M. Nagorney Diverse clinical and pathologic features of gastric carcinoid and the relevance of hypergastrinemia World J. Surg. 1994 18 473 480
63. Green D. M. A. E. Bishop G. Rindi F. I. Lee M. J. Daly J. Domin S. R. Bloom J. M. Polak Enterochromaffin-like cell populations in human fundic mucosa: quantitative studies of their variations with age, sex, and plasma gastrin levels J. Pathol. 1989 157 235 241
64. Guo Y. S. C. M. Townsend Jr.. Roles of gastrointestinal hormones in pancreatic cancer J. Hepatobiliary Pancreat. Surg. 2000 7 276 285
65. 2 receptor Gastroenterology 2003 124 615 625
66. Harris J. C. P. A. Clarke A. Awan J. Jankowski S. A. Watson An antiapoptotic role for gastrin and the gastrin/CCK-2 receptor in Barrett's esophagus Cancer Res. 2004a 64 1915 1919
67. Harris J. C. A. D. Gilliam A. J. McKenzie S. A. Evans A. M. Grabowska P. A. Clarke D. F. McWilliams S. A. Watson The biological and therapeutic importance of gastrin gene expression in pancreatic adenocarcinomas Cancer Res. 2004b 64 5624 5631
68. Hatlebakk J. G. A. Hyggen P. H. Madsen P. O. Walle T. Schulz P. Mowinckel T. Bernklev A. Berstad Heartburn treatment in primary care: randomised, double blind study for 8 weeks Brit. Med. J. 1999 319 550 553
69. Havu N. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion Digestion 1986 35 Suppl. 1 42 55
70. Håkanson R. J. Axelson R. Ekman F. Sundler Hypergastrinaemia evoked by omeprazole stimulates growth of gastric mucosa but not of pancreas of intestines in hamster, guinea pig and chicken Regul. Pept. 1988 23 105 115
71. Håkanson R. H. Blom E. Carlsson H. Larsson B. Ryberg F. Sundler Hypergastrinemia produces trophic effects in stomach but not in pancreas and intestines Regul. Pept. 1986 13 225 233
72. Håkanson R. F. Sundler Mechanisms for the development of gastric carcinoids Digestion 1986 35 Suppl. 1 1 151
73. Helander H. F. K. Rutgersson K. G. Helander J. P. Pisegna J. D. Gardner R. T. Jensen P. N. Maton Stereologic investigations of human gastric mucosa: II. Oxyntic mucosa from Zollinger-Ellison syndrome Scand. J. Gastroenterol. 1992 27 875 883
74. Hillman L. C. L. Chiragakis B. Shadbolt G. L. Kaye A. C. Clarke Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus Med. J. Aust. 2004 180 387 391
75. Hirschowitz B. I. M. M. Haber Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole Aliment. Pharmacol. Ther. 2001 15 87 103
76. Hirschowitz B. I. J. Simmons J. Mohnen Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non-ZE hypersecretors: a prospective 10-year study Aliment. Pharmacol. Ther. 2001 15 1795 1806
77. Hirschowitz B. I. J. Simmons J. Mohnen Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study Clin. Gastroenterol. Hepatol. 2005 3 39 48
78. Holtmann G. C. Cain P. Malfertheiner Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole Gastroenterology 1999 117 11 16
79. 2receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome Gastroenterology 1985 88 1026 1033
80. Hsing A. W. L. E. Hansson J. K. McLaughlin O. Nyren W. J. Blot A. Ekbom J. F. Fraumeni Jr.. Pernicious anemia and subsequent cancer. A population-based cohort study Cancer 1993 71 745 750
81. Jansen J. B. E. C. Klinkenberg-Knol S. G. Meuwissen J. W. De Bruijne H. P. Festen P. Snel A. E. Luckers I. Biemond C. B. Lamers Effect of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis Gastroenterology 1990 99 621 628
82. Jensen R. T. Recent insights from studies of gastrinomas In Gastrin in the new millenium (2004) Eds. Merchant J. L. Buchan A. M. J. Wang T. C. The CURE Foundation Los Angeles, CA 2004 pp. 339 352
83. Jensen R. T. Use of omeprazole and other proton pump inhibitors in the Zollinger-Ellison syndrome In Milestones in Drug Therapy Ed. Olbe L. Birkhauser Verlag AG Publish. Co. Basel, Switzerland 1999 pp. 205 221
84. Jensen R. T. Gastrinoma as a model for prolonged hypergastrinemia in man In Gastrin Ed. Walsh J. H. Raven Press Publishing Co. New York, NY 1993 pp. 373 393
85. Jensen R. T. Involvement of cholecystokinin/gastrin-related peptides and their receptors in clinical gastrointestinal disorders Pharmacology & Toxicology 2002 91 333 350
86. Jensen R. T. M. J. Collen K. E. McArthur J. M. Howard P. N. Maton J. A. Cherner J. D. Gardner Comparison of the effectiveness of ranitidine and cimetidine in inhibiting acid secretion in patients with gastric acid hypersecretory states Amer. J. Med. 1984 77(5B) 90 105
87. Jensen R. T. J. D. Gardner Gastrinoma In The pancreas: Biology, pathobiology and disease 2 edn. Eds. Go V. L. W. DiMagno E. P. Gardner J. D. Lebenthal E. Reber H. A. Scheele G. A. Raven Press Publishing Co. New York 1993 pp. 931 978
88. Jensen R. T. D. C. Metz P. D. Koviack K. M. Feigenbaum Prospective study of the long-term efficacy and safety of lansoprazole in patients with Zollinger-Ellison syndrome Aliment. Pharmacol. Ther. 1993 7 Suppl. 1 41 50
89. Karlson B. M. A. Ekbom S. Waeholder J. K. McLaughlin A. W. Hsing Cancer of the upper gastrointestinal tract among patients with pernicious anemia: a case-cohort study Scand. J. Gastroenterol. 2001 35 847 851
90. Kittang E. E. Aadland H. Schjonsby K. Rohss The effect of omeprazole on gastric acidity and the absorption of liver cobalamins Scand. J. Gastroenterol. 1987 22 156 160
91. Kittang E. E. Aadlang H. Schonsby Effect of omeprazole on the secretion of intrinsic factor, gastric acid and pepsin in man Gut 1985 26 594 598
92. Klinkenberg-Knol E. C. H. P. M. Festen J. B. M. J. Jansen C. B. H. W. Lamers F. Nelis P. Snel A. Luckers C. P. M. Dekkers N. Havu S. G. M. Meuwissen Long-term treatment wih omeprazole for refractory reflux esophagitis: efficacy and safety Ann. Intern. Med. 1994 121 161 167
93. Klinkenberg-Knol E. C. F. Nelis J. Dent P. Snel B. Mitchell P. Prichard D. Lloyd N. Havu M. H. Frame J. Roman A. Walan a long-term study group Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety and influence on gastric mucosa Gastroenterology 2000 118 661 669
94. Koh T. J. Extragastric effects of gastrin gene knock-out mice Pharmacology & Toxicology 2002 91 368 374
95. Kokkola A. S. M. Sjoblom R. Haapiainen P. Sipponen P. Puolakkainen H. Jarvinen The risk of gastric carcinoma and carcinoid tumours in patients with pernicious anaemia. A prospective follow-up study Scand. J. Gastroenterol. 1998 33 88 92
96. Konturek P. C. A. Nikiforuk J. Kania M. Raithel E. G. Hahn S. Mühldorfer Activation of NFκ represents the central event in the neoplastic progression associated with Barrett's esophagus: a possible link to the inflammation and overexpression of COX-2, PPARγ and growth factors Dig. Dis. Sci. 2004 49 1075 1083
97. Koop H. Review article: metabolic consequences of long-term inhibition of acid secretion by omeprazole Aliment. Pharmacol. Ther. 1992 6 399 406
98. Koop H. M. G. Bachem Serum iron, ferritin, and vitamin B12 during prolonged omeprazole therapy J. Clin. Gastroenterol. 1992 14 288 292
99. Kuipers E. J. L. Lundell E. C. Klinkenberg-Knol N. Havu H. P. Festen B. Liedman C. B. Lamers J. B. Jansen J. Dalenback P. Snel G. F. Nelis S. G. Meuwissen Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication New Engl. J. Med. 1996 334 1018 1022
100. Kuipers E. J. S. G. M. Meuwissen The efficacy and safety of long-term omeprazole treatment for gastroesophageal reflux disease Gastroenterology 2000 118 795 801
101. Kuipers E. J. G. F. Nelis E. C. Klinkenberg-Knol P. Snel D. Goldfain J. J. Kolkman H. P. Festen J. Dent P. Zeitoun N. Havu M. Lamm A. Walan Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial Gut 2004 53 12 20
102. Kuipers E. J. A. M. Uyterlinde A. S. Pena H. J. Hazenberg E. Bloemena J. Lindeman E. C. KlinkenbergKnol S. G. Meuwissen Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety Amer. J. Gastroenterol. 1995 90 1401 1406
103. Labenz J. A. L. Blum E. Bayerdorffer A. Meining M. Stolte G. Borsch Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis Gastroenterology 1997 112 1442 1447
104. Laine L. D. Ahnen C. McClain E. Solcia J. H. Walsh Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors Aliment. Pharmacol. Ther. 2000 14 651 668
105. Lamberts R. W. Creutzfeldt F. Stockmann U. Jacubaschke S. Maas G. Brunner Long term omeprazole treatment in man: effects on gastric endocrine cell populations Digestion 1988 39 126 135
106. Lamberts R. W. Creutzfeldt H. G. Struber G. Brunner E. Solcia Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis Gastroenterology 1993 104 1356 1370
107. Larsson H. E. Carlsson B. Ryberg J. Fryklund B. Wallmark Rat parietal cell function after prolonged inhibition of gastric acid secretion Amer. J. Physiol. 1988 254 G33 G39
108. Lehy T. G. Cadiot M. Mignon P. Ruszniewski S. Bonfils Influence of multiple endocrine neoplasia type 1 on gastric endocrine cells in patients with the Zollinger-Ellison syndrome Gut 1992 33 1275 1279
109. Lehy T. M. Mignon G. Cadiot L. Elouaer-Blanc P. Ruszniewski M. J. Lewin S. Bonfils Gastric endocrine cell behavior in Zollinger-Ellison patients upon long-term potent antisecretory treatment Gastroenterology 1989 96 1029 1040
110. Ley L. M. A. Becker R. Luhmann P. Sander P. W. Lucker Pharmacodynamic effects of 3-day intravenous treatment with pantoprazole or ranitidine after 10 days of oral ranitidine Meth. Find. Exp. Clin. Pharmacol. 2005 27 25 29
111. Ligumsky M. J. Lysy G. Siguencia Y. Friedlander Effect of long-term, continuous versus alternate-day omeprazole therapy on serum gastrin in patients treated for reflux esophagitis J. Clin. Gastroenterol. 2001 33 32 35
112. Lindenbaum J. I. H. Rosenberg P. W. Wilson S. P. Stabler R. H. Allen Prevalence of cobalamin deficiency in the Framingham elderly population Amer. J. Clin. Nutr. 1994 60 2 11
113. Lundell L. P. Miettinen H. E. Myrvold S. A. Pedersen K. Thor A. Andersson J. Hattlebakk N. Havu E. Janatuinen K. Levander B. Liedman P. Nystrom Lack of effect of acid suppression therapy on gastric atrophy. Nordic gerd study group Gastroenterology 1999 117 319 326
114. Malfertheiner P. F. Megraud C. O'Morain A. P. Hungin R. Jones A. Axon D. Y. Graham G. Tytgat Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report Aliment. Pharmacol Ther. 2002a 16 167 180
115. Malfertheiner P. F. Megraud C. O'Moran A. P. Hungin R. Jones A. Axon D. Y. Graham G. Tytgat European Helicobacter Pylori Study Group (EHPSG) Current concepts in the management of Helicobacter pylori infection - the Maastricht 2 - 2000 Consensus Report Aliment. Pharmacol. Ther. 2002b 16 167 180
116. Marcuard S. P. L. Albernaz P. G. Khazanie Omeprazole therapy causes malabsorption of cyanocobalamin (Vitamin B12) Ann. Intern. Med. 1994 120 211 215
117. Maton P. Risks of hypergastrinemia Dig. Dis. Sci. 1995 13 1 2
118. Maton P. N. E. E. Lack M. J. Collen M. J. Cornelius E. David J. D. Gardner R. T. Jensen The effect of Zollinger-Ellison syndrome and omeprazole therapy on gastric oxyntic endocrine cells Gastroenterology 1990 99 943 950
119. Maton P. N. J. A. Norton L. K. Nieman J. L. Doppman R. T. Jensen Multiple endocrine neoplasia type II with Zollinger-Ellison syndrome caused by a solitary pancreatic gastrinoma J. Amer. Med. Ass. 1989a 262 535 537
120. Maton P. N. R. Vinayek H. Frucht K. A. McArthur L. S. Miller Z. A. Saeed J. D. Gardner R. T. Jensen Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study Gastroenterology 1989b 97 827 836
121. Mattsson H. N. Havu J. Brautigam K. Carlsson L. Lundell E. Carlsson Partial gastric corpectomy results in hypergastrinemia and development of gastric enterochromaffinlike-cell carcinoids in the rat Gastroenterology 1991 100 311 319
122. McColl K. E. Helicobacter pylori infection and long term proton pump inhibitor therapy Gut 2004 53 57
123. Metz D. C. R. V. Benya V. A. Fishbeyn J. R. Pisegna M. Orbuch D. B. Strader J. A. Norton R. T. Jensen Prospective study of the need for long-term antisecretory therapy in patients with ZollingerEllison syndrome following successful curative gastrinoma resection Aliment. Pharmacol. Ther. 1993a 7 #3 247 257
124. Metz D. C. R. T. Jensen Advances in gastric antisecretory therapy in Zollinger-Ellison syndrome In Endocrine Tumors of the Pancreas: Recent advances in research and management. Series: Frontiers of Gastrointestinal Research Eds. Mignon M. Jensen R. T. S. Karger Basel, Switzerland 1995 pp. 240 257
125. Metz D. C. J. R. Pisegna V. A. Fishbeyn R. V. Benya K. M. Feigenbaum P. D. Koviack R. T. Jensen Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high Gastroenterology 1992 103 1498 1508
126. Metz D. C. J. R. Pisegna G. L. Ringham K. M. Feigenbaum P. D. Koviack P. N. Maton J. D. Gardner R. T. Jensen Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome Dig. Dis. Sci. 1993b 38 245 256
127. Metz D. C. D. B. Strader M. Orbuch P. D. Koviack K. M. Feigenbaum R. T. Jensen Use of omeprazole in Zollinger-Ellison: A prospective nine-year study of efficacy and safety Aliment. Pharmacol. Ther. 1993c 7 597 610
128. Meuwissen S. G. M. E. Craanen E. J. Kuipers Gastric mucosal morphological consequences of acid suppression: a balanced view Best Pract. Res. Clin Gastroenterol. 2001 15 497 510
129. Miller L. S. R. Vinayek H. Frucht J. D. Gardner R. T. Jensen P. N. Maton Reflux esophagitis in patients with Zollinger-Ellison syndrome Gastroenterology 1990 98 341 346
130. Mitchell S. L. K. Rockwood The association between antiulcer medication and initiation of cobalamin replacement in older persons J. Clin. Epidemiol. 2001 54 531 534
131. Moayyedi P. C. Wason R. Peacock A. Walan K. Bardhan A. T. Axon M. F. Dixon Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression Helicobactor 2000 5 206 214
132. Modlin I. M. K. D. Lye M. Kidd Carcinoid tumors of the stomach Surg. Oncol. 2003 12 153 172
133. Modlin I. M. L. H. Tang The gastric enterochromaffin-like cell: an enigmatic cellular link Gastroenterology 1996 111 783 810
134. Moore T. C. L. I. Jepeal M. O. Boylan S. K. Singh N. Boyd D. G. Beer A. J. Chang M. M. Wolfe Gastrin stimulates receptor-mediated proliferation of human esophageal adenocarcinoma cells Regul. Pept. 2004 120 195 203
135. Morisset J. J. Laine M. Biernat S. Julien What are the pancreatic target cells for gastrin and its CCKB receptor? Is this a couple for cancerous cells? Med. Sci. Monit. 2004 10 RA246
136. Morris C. D. G. R. Armstrong G. Bigley H. Green S. E. Attwood Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence Amer. J. Gastroenterol. 2001 96 990 996
137. Naunton M. G. M. Peterson M. D. Bleasel Overuse of proton pump inhibitors J. Clin. Pharm. Ther. 2000 25 330 340
138. Norton J. A. H. R. Alexander D. L. Fraker D. J. Venzon R. T. Jensen Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases or survival in patients with Zollinger-Ellison syndrome (ZES)? Ann Surg. 2004a 239 617 626
139. Norton J. A. D. L. Fraker H. R. Alexander D. J. Venzon J. L. Doppman J. Serrano S. U. Goebel P. Peghini P. K. Roy F. Gibril R. T. Jensen Surgery to cure the Zollinger-Ellison syndrome New Engl. J. Med. 1999 341 635 644
140. Norton J. A. R. T. Jensen Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome Ann. Surg. 2004 240 757 773
141. Norton J. A. M. L. Melcher F. Gibril R. T. Jensen Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgery Surgery 2004b 136 1267 1274
142. Orbuch M. D. J. Venzon I. A. Lubensky H. C. Weber F. Gibril R. T. Jensen Prolonged hypergastrinemia does not increase the frequency of colonic neoplasia in patients with Zollinger-Ellison syndrome Dig. Dis. Sci. 1996 41 604 613
143. Peghini P. L. B. Annibale C. Azzoni M. Milione V. D. Corleto F. Gibril D. J. Venzon G. Delle Fave C. Bordi R. T. Jensen Effect of chronic hypergastrinemia on human enterochromaffin-like cells: insights from patients with sporadic gastrinomas Gastroenterology 2002 123 68 85
144. Pisegna J. R. J. A. Norton G. G. Slimak D. C. Metz P. N. Maton R. T. Jensen Effects of curative resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome Gastroenterology 1992 102 767 778
145. 2 blockade and gastric carcinoid tumours in the rat Gut 1985 26 1284 1295
146. 2 blockade Gut 1986 27 1338 1346
147. Prewett E. J. M. Hudson C. U. Nwokolo A. M. Sawyerr R. E. Pounder Nocturnal intragastric acidity during and after a period of dosing with either ranitidine or omeprazole Gastroenterology 1991 100 873 877
148. Qvigstad G. J. S. Arnestad E. Brenna H. L. Waldum Treatment with proton pump inhibitors induces tolerance to histamine-2 receptor antagonists in Helicobacter pylori-negative patients Scand. J. Gastroenterol. 1998 33 1244 1248
149. Qvigstad G. S. Falkmer B. Westre H. L. Waldum Clinical and histopathological tumour progression in ECL cell carcinoids ("ECLomas" ) APMIS 1999 107 1085 1092
150. Qvigstad G. T. Qvigstad B. Westre A. K. Sandvik E. Brenna H. L. Waldum Neuroendocrine differentiation in gastric adenocarcinomas associated with severe hypergastrinemia and/or pernicious anemia APMIS 2002 110 132 139
151. Qvigstad G. A. K. Sandvik E. Brenna S. Aase H. L. Waldum Detection of chromogranin A in human gastric adenocarcinomas using a sensitive immunohistochemical technique Histochem. J 2000 32 551 556
152. Qvigstad G. H. Waldum Rebound hypersecretion after inhibition of gastric acid secretion Basic & Clinal Pharmacology & Toxicology 2004 94 202 208
153. Rehfeld J. F. Gastrin and colorectal cancer: A never-ending dispute? (Editorial) Gastroenterology 1995 108 1307 1310
154. Rehfeld J. F. W. W. van Solinge The tumor biology of gastrin and cholecystokinin Adv. Cancer Res. 1994 63 295 347
155. Reilly J. P. Safety profile of the proton-pump inhibitors Am. J. Health Syst. Pharm. 1999 56 S11 S17
156. Renga M. G. Brandi G. M. Paganelli C. Calabrese S. Papa A. Tosti P. Tomassetti M. Miglioli G. Biasco Rectal cell proliferation and colon cancer risk in patients with hypergastrinemia Gut 1997 41 330 332
157. Rindi G. C. Azzoni S. La Rosa C. Klersy D. Paolotti S. Rappel M. Stolte C. Capella C. Bordi E. Solcia ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis Gastroenterology 1999 116 532 542
158. Rindi G. C. Bordi S. Rappel S. La Rosa M. Stolte E. Solcia Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior World J. Surg. 1996 20 168 172
159. Robinson M. Review article: current perspectives on hypergastrinaemia and enterochromaffin-like-cell hyperplasia Aliment. Pharmacol. Ther. 1999 13 5 10
160. Roy P. D. J. Venzon K. M. Feigenbaum P. D. Koviack S. Bashir J. V. Ojeaburu F. Gibril R. T. Jensen Gastric secretion in Zollinger-Ellison syndrome: correlation with clinical expression, tumor extent and role in diagnosis - A prospective NIH study of 235 patients and review of the literature in 984 cases Medicine(Baltimore) 2001 80 189 222
161. Roy P. D. J. Venzon H. Shojamanesh A. Abou-Saif P. Peghini J. L. Doppman F. Gibril R. T. Jensen Zollinger-Ellison syndrome: clinical presentation in 261 patients Medicine 2000 79 379 411
162. Rucker R. B. B. Lonnerdal C. L. Keen Intestinal absorption of nutritionally important trace elements In Physiology of the gastrointestinal tract 3rd edn. Ed. Johnson L. R. Raven Press New York 1994 pp. 2183 2202
163. Ruscin J. M. R. L. 2. Page R. J. Valuck Vitamin B(12) deficiency associated with histamine(2)-receptor antagonists and a proton-pump inhibitor Ann. Pharmacother. 2002 36 812 816
164. Saeed Z. A. D. J. Evans Jr.. D. G. Evans M. J. Cornelius P. N. Maton R. T. Jensen D. Y. Graham Helicobacter pylori and the Zollinger-Ellison syndrome Dig. Dis. Sci. 1991 36 15 18
165. Sagar M. I. Janczewska A. Ljungdahl L. Bertilsson R. Seensalu Effect of CYP2C19 polymorphism on serum levels of vitamin B12 in patients on long-term omeprazole treatment Aliment. Pharmacol. Ther. 1999 13 453 458
166. Saltzman J. R. J. A. Kemp B. B. Golner M. C. Pedrosa G. E. Dallal R. M. Russell Effect of hypochlorhydria due to omeprazole treatment or atrophic gastritis on protein-bound vitamin B12 absorption J. Amer. Coll. Nutr. 1994 13 584 591
167. Sanduleanu S. M. Stridsberg D. Jonkers W. Hameeteman I. Biemond G. Lundqvist C. Lamers R. W. Stockbrügger Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study Aliment. Pharmacol. Ther. 1999 13 145 153
168. Sandvik A. K. E. Brenna H. L. Waldum Review article: the pharmacological inhibition of gastric acid secretion-tolerance and rebound Aliment. Pharmacol. Ther. 1997 11 1013 1018
169. Schafer L. W. D. E. Larson L. J. 3.. Melton J. A. Higgins A. R. Zinsmeister Risk of development of gastric carcinoma in patients with pernicious anemia: a population-based study in Rochester, Minnesota Mayo Clin. Proc. 1985 60 444 448
170. Schenk B. E. H. P. M. Festen E. J. Kuipers E. C. Klinkenberg-Knol G. M. Meuwissen Effect of short- and long-term treatment with omeprazole on the absorption and serum levels of cobalamin Aliment. Pharmacol. Ther. 1996 10 541 545
171. Schenk B.E. E. J. Kuipers E. C. Klinkenberg-Knol E. Bloemena G. F. Nelis H. P. M. Festen E. H. Jansen I. Biemond C. B. Lamers S. G. Meuwissen Hypergastrinemia during long-term omeprazole therapy: influences of vagal nerve function, gastric emptying and Helicobacter pylori infection Aliment. Pharmacol. Ther. 1998 12 605 612
172. Schenk B. E. E. J. Kuipers E. C. Klinkenberg-Knol E. C. Bloemena M. Sandell G. F. Nelis P. Snel H. P. Festen S. G. Meuwissen Atrophic gastritis during long-term omeprazole therapy affects serum vitamin B12 levels Aliment. Pharmacol. Ther. 1999 13 1343 1346
173. Schwizer W. M. Thumshirn J. Dent I. Guldenschuh D. Menne G. Cathomas M. Fried Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial Lancet 2001 357 1738 1742
174. Seetharam B. Gastrointestinal absorption and transport of cobalamin (vitamin B12) In Physiology of the gastrointestinal tract Third edn. Eds. Johnson L. R. Alpers D. H. Christensen J. Jacobson E. D. Walsh J. H. Raven Press New York 1994 pp. 1997 2026
175. Sharma V. R. M. A. Brannon E. A. Carloss Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia South Med. J. 2004 97 887 889
176. Shulkes A. G. S. Baldwin Biology of gut cholecystokinin and gastrin receptors Clin. Exp. Pharmacol. Physiol. 1997 24 209 216
177. Singh P. A. Indaram R. Greenberg V. Visvalingam S. Bank Long term omeprazole therapy for reflux esophagitis: follow-up in serum gastrin levels, EC cell hyperplasia and neoplasia World J. Gastroenterol. 2000 789 792
178. Sjöblom S. M. P. Sipponen S. L. Karonen H. J. Jarvinen Mucosal argyrophil endocrine cells in pernicious anaemia and upper gastrointestinal carcinoid tumours J. Clin. Pathol. 1989 42 371 377
179. Skikne B. S. S. R. Lynch J. D. Cook Role of gastric acid in food iron absorption Gastroenterology 1981 81 1068 1071
180. Smith A. D. D. Gillen K. M. Cochran E. El-Omar K. E. McColl Dyspepsia on withdrawal of ranitidine in previously asymptomatic volunteers Amer. J. Gastroenterol. 1999 94 1209 1213
181. Smith A. M. S. A. Watson Review article: gastrin and colorectal cancer Aliment. Pharmacol. Ther. 2000 14 1231 1247
182. Smith J. P. W. B. Stanley M. F. Verderame I. S. Zagon The functional significance of the cholecystokinin-C (CCK-C) receptor in human pancreatic cancer Pancreas 2004 29 271 277
183. 2-blockade: placebo-controlled studies of 24-hour acidity and gastrin Aliment. Pharmacol. Ther. 1990 4 Suppl. 1 47 63
184. Sobhani I. T. Lehy P. Laurent-Puig G. Cadiot P. Ruszniewski M. Mignon Chronic endogenous hypergastrinemia in humans: evidence for a mitogenic effect on the colonic mucosa Gastroenterology 1993 105 22 30
185. Solcia E. C. Bordi W. Creutzfeldt Y. Dayal A. D. Dayan S. Falkmer L. Grimelius N. Havu Histopathological classification of nonantral gastric endocrine growths in man Digestion 1988 41 185 200
186. Solcia E. C. Capella R. Fiocca G. Rindi J. Rosai Gastric argyrophil carcinoidosis in patients with Zollinger-Ellison syndrome due to type 1 multiple endocrine neoplasia. A newly recognized association Amer. J. Surg. Pathol. 1990 14 503 513
187. Solcia E. R. Fiocca N. Havu A. Dalvag R. Carlsson Gastric endocrine cells and gastritis in patients receiving long- term omeprazole treatment Digestion 1992 51 Suppl. 1 82 92
188. Solcia E. R. Fiocca L. Villani O. Luinetti C. Capella Hyperplastic, dysplastic, and neoplastic enterochromaffin-like-cell proliferations of the gastric mucosa Classification and histogenesis. Amer. J. Surg. Pathol. 1995 19 S1 S7
189. Solcia E. G. Rindi N. Havu G. Elm Qualitative studies of gastric endocrine cells in patients treated longterm with omeprazole Scand. J. Gastroenterol. 1989 24 129 137
190. Solcia E. G. Rindi S. LaRosa C. Capella Morphological, molecular, and prognostic aspects of gastric endocrine tumors Microsc. Res. Tech. 2000 48 339 348
191. Sonnenberg A. H. B. El-Serag Clinical epidemiology and natural history of gastroesophageal reflux disease Yale J. Biol. Med. 1999 72 81 92
192. Spencer A. J. T. A. Barbolt D. C. Henry C. T. Eason R. J. Sauerschell F. W. Bonner Gastric morphological changes including carcinoid tumors in animals treated with a potent hypolipidemic agent, ciprofibrate Toxicol. Pathol. 1989 17 7 15
193. Stewart C. A. B. Termanini V. E. Sutliff J. Serrano F. Yu F. Gibril R. T. Jensen Assessment of the risk of iron malabsorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy Aliment. Pharmacol. Ther. 1998 12 83 98
194. Stolte M. A. Meining J. M. Schmitz T. Alexandridis E. Seifert Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease Aliment. Pharmacol. Ther. 1998 12 247 253
195. Strader D. B. S. Benjamin M. Orbuch I. A. Lubensky C. Weber F. Gibril R. T. Jensen D. M. Metz Esophageal function and occurrence of Barrett's esophagus in Zollinger-Ellison syndrome Digestion 1995 56 347 356
196. Sundler F. R. Hakanson E. Carlsson H. Larsson H. Mattsson Hypergastrinemia after blockade of acid secretion in the rat: trophic effects Digestion 1986 35 56 69
197. Svendsen J. H. C. Dahl L. B. Svendsen P. M. Christiansen Gastric cancer risk in achlorhydric patients. A long-term follow-up study Scand. J. Gastroenterol. 1986 21 16 20
198. Symonds D. A. H. E. Ramsey Adenocarcinoma arising in Barrett's esophagus with Zollinger-Ellison syndrome Amer. J. Clin. Pathol. 1980 73 823 826
199. Takaishi S. G. Cui D. M. Frederick J. E. Carlson J. Houghton A. Varro G. J. Dockray Z. Ge M. T. Whary A. B. Rogers J. G. Fox T. C. Wang Synergistic inhibitory effects of gastrin and histamine receptor antagonists on Helicobacter-induced gastric cancer Gastroenterology 2005 128 1965 1983
200. Takhar A. S. O. Eremin S. A. Watson The role of gastrin in colorectal carcinogenesis Surgeon 2004 2 251 257
201. Termanini B. F. Gibril V. E. Sutliff III. F. Yu D. J. Venzon R. T. Jensen Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome Amer. J. Med. 1998 104 422 430
202. Thomas R. P. M. R. Hellmich C. M. Townsend Jr.. B. M. Evers Role of gastrointestinal hormones in the proliferation of normal and neoplastic tissues Endocr. Rev. 2003 24 571 599
203. Uemura N. S. Okamoto S. Yamamoto N. Matsumura S. Yamaguchi M. Yamakido K. Taniyama N. S. R. J. Sasaki Helicobacter pylori infection and the development of gastric cancer New Engl. J. Med. 2001 345 784 789
204. 2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults J. Clin. Epidemiol. 2004 57 422 428
205. Van Nieuwenhove Y. T. De Backer D. Chen R. Hakanson G. Willems Gastrin stimulates epithelial cell proliferation in the oesophagus of rats Virchows Arch. 1998 432 371 375
206. Verdu E. F. D. Armstrong R. Fraser F. Viani J. P. Idstrom C. Cederberg A. L. Blum Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole Gut 1995a 36 539 543
207. Verdu E. F. D. Armstrong J. P. Idstrom J. Labenz M. Stolte G. Dorta G. Borsch A. L. Blum Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole Gut 1995b 37 743 748
208. Waldum H. L. S. Aase I. Kvetnoi E. Brenna A. K. Sandvik U. Syversen G. Johnsen L. Vatten J. M. Polak Neuroendocrine differentiation in human gastric carcinoma Cancer 1998a 83 435 444
209. Waldum H. L. J. S. Arnestad E. Brenna I. Eide U. Syversen A. K. Sandvik Marked increase in gastric acid secretory capacity after omeprazole treatment Gut 1996 39 649 653
210. Waldum H. L. E. Brenna Personal review: is profound acid inhibition safe? Aliment- Pharmacol. Ther. 2000 14 15 22
211. Waldum H. L. E. Brenna A. K. Sandvik Long-term safety of proton pump inhibitors: risks of gastric neoplasia and infections Expert Opin. Drug Saf 2002 1 29 38
212. Waldum H. L. I. M. Kvetnoi R. Sylte B. Schulze T. C. Martinsen A. K. Sandvik The effect of the peroxisome proliferator ciprofibrate on the gastric mucosa and particularly the gastrin cell J Mol. Endocrinol. 1998b 20 111 117
213. Wang T. C. C. A. Dangler D. Chen J. R. Goldenring T. Koh R. Raychowdhury R. J. Coffey S. Ito A. Varro G. J. Dockray J. G. Fox Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer Gastroenterology 2000 118 36 47
214. Wangberg B. O. Nilsson E. Theodorsson I. M. Modlin A. Dahlström H. Ahlman Are enterochromaffinlike cell tumours reversible? An experimental study on gastric carcinoids induced in Mastomys by histamine2-receptor blockade Regul. Pept. 1995 56 19 33
215. Weber H. C. D. J. Venzon R. T. Jensen D. C. Metz Studies on the interrelation between ZollingerEllison syndrome, Helicobacter pylori and proton pump inhibitor therapy Gastroenterology 1997 112 84 91
216. 2-receptor antagonists. An overview Scand. J. Gastroenterol. Suppl. 1992 193 14 19
217. Wolters M. A. Strohle A. Hahn Cobalamin: a critical vitamin in the elderly Prev. Med. 2004 39 1256 1266
218. Wu J. C. F. K. Chan J. Y. Ching W. K. Leung Y. Hui R. Leong S. C. Chung J. J. Sung Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux disease: a double blind, placebo controlled, randomised trial Gut 2004 53 174 179
219. Ye W. O. Nyren Risk of cancers of the oesophagus and stomach by histology or subsite in patients hospitalised for pernicious anaemia Gut 2003 52 938 941
220. Yeomans N. D. J. Dent Personal review: alarmism or legitimate concerns about long-term suppression of gastric acid secretion? Aliment. Pharmacol. Ther. 2000 14 267 271
221. Younes M. Can proton pump inhibitors be blamed for the rising incidence of esophageal cancer? [Letter to Ed.] Gastroenterology 2003 125 1912
222. Yu F. D. J. Venzon J. Serrano S. U. Goebel J. L. Doppman F. Gibril R. T. Jensen Prospective study of the clinical course, prognostic factors and survival in patients with longstanding Zollinger-Ellison syndrome J. Clin. Oncol. 1999 17 615 630